Sodertalje, Sweden

Inger Kers

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 6.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Södertälje, SE (2009 - 2012)
  • Sodertalje, SE (2010 - 2012)

Company Filing History:


Years Active: 2009-2012

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Inger Kers: Innovator in Pharmaceutical Compounds

Introduction

Inger Kers is a prominent inventor based in Södertälje, Sweden. She has made significant contributions to the field of pharmaceuticals, holding a total of 4 patents. Her work focuses on developing new compounds and therapeutic applications that address various medical needs.

Latest Patents

Inger's latest patents include innovative compounds that relate to new salts, solvates, and pharmaceutical compositions. One of her notable inventions involves N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives, which are aimed at treating pain. These inventions not only describe the compounds but also detail the processes for their preparation and the intermediates used in their synthesis.

Career Highlights

Inger Kers is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. Her role at AstraZeneca allows her to leverage her expertise in pharmaceutical innovation, contributing to the development of new therapies that can improve patient outcomes.

Collaborations

Inger has collaborated with notable colleagues, including Yevgeni Besidski and Martin Nylöf. These partnerships enhance her research and development efforts, fostering a collaborative environment that drives innovation in the pharmaceutical sector.

Conclusion

Inger Kers is a dedicated inventor whose work in pharmaceutical compounds has the potential to make a significant impact on pain management and therapy. Her contributions to AstraZeneca and her innovative patents highlight her role as a key player in the field of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…